Global Phase 3 data for 177Lu‑PSMA‑I&T have met the primary endpoint with statistically significant, clinically meaningful benefit in metastatic castration‑resistant prostate cancer, and Japan has now dosed the first patient in a registrational, multicenter, open‑label, single‑arm Phase 2 that will assess efficacy and safety in PSMA‑positive mCRPC.
The core development is a coordinated theranostic push by Curium, PeptiDream, and PDRadiopharma. The Japanese Phase 2 will leverage bridging from Curium’s ongoing global trials while using 64Cu‑PSMA‑I&T PET to confirm PSMA positivity before treatment—aligning patient selection and therapeutic delivery within one program. In parallel, Curium’s diagnostic franchise is advancing through Phase 3 SOLAR studies in biochemical recurrence and in newly diagnosed, higher‑risk surgical candidates, with earlier first‑in‑human data meeting co‑primary detection endpoints. In Japan, PDRadiopharma will lead regulatory filing, local manufacturing, commercialization, and distribution; Curium remains responsible for global development and is transferring technology to establish domestic production, including a high‑throughput copper‑64 line.
Strategically, this is an acceleration plan for Japan built on regulatory bridging, local isotope capacity, and a locked diagnostic‑to‑therapeutic workflow. A single‑arm registrational design signals confidence in the global dataset while aiming to compress time to market under PMDA’s well‑established framework for foreign data extrapolation. It also positions Curium in a PSMA radioligand market that already has regulatory precedent in major regions and is increasingly defined by integrated imaging‑therapy pathways. The copper‑64 choice has operational consequences: longer half‑life relative to generator‑based tracers can favor centralized manufacturing and wider geographic reach, but it increases the importance of robust radiochemistry and distribution controls. On the therapeutic side, lutetium‑177 supply continuity, labeling reliability, and standardized dosing workflows remain gating factors for scale.
For sites, the program reinforces the need to operate as theranostic hubs: PSMA PET screening, coordination of imaging‑to‑therapy intervals, radiation safety, and waste handling must be harmonized to minimize screen failures and treatment delays. Centers with established nuclear medicine capabilities will be advantaged, but sponsor support for site enablement—calibration, SOPs, and just‑in‑time logistics—will be decisive for enrollment velocity. CROs should expect a network that skews to nuclear medicine‑anchored institutions and will need tight oversight of radiopharmacy readiness and isotope delivery SLAs. Regulators will focus on the adequacy of bridging plus Japanese safety and exposure data, the reproducibility of imaging‑based eligibility, and consistency of efficacy across subgroups. Manufacturers and vendors linked to Lu‑177 and Cu‑64 production, cold kit supply, and transport will see near‑term demand signals, but the ramp will hinge on validated domestic lines and contingency planning for isotope shortages.
The next markers to watch are the Japanese Phase 2 protocol specifics—primary endpoint selection, sample size, interim analysis cadence—and how PMDA frames the sufficiency of global Phase 3 data alongside local evidence for registration. Clarity on the role of 64Cu‑PSMA‑I&T as the required imaging modality for selection, and any companion‑diagnostic‑like expectations, will shape site setup and payer adoption. Competitive dynamics will turn on manufacturing resilience, ease of site onboarding, and demonstrated real‑world throughput as much as on efficacy deltas. The principal risks remain isotope supply constraints, variability in site nuclear medicine capacity, and potential regulator requests for comparative data. If the bridging strategy holds and operations scale cleanly, Japan could see a faster path to a PSMA theranostic suite; if not, timelines will slip toward additional local evidence generation and incremental capacity build‑out.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
